U.S Biosimilars Market Outlook 2030: Industry Insights & Opportunity Evaluation, 2019-2030


A critical part of the overall production process is the production and evaluation of bio-referential biologics. In the conservation of feasibility and consistency between initial and biosimilar goods the rules for biosimilars play an important role.



U.S Biosimilars Market by Product Type (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins); By Application (Chronic & Autoimmune Disorders, Blood Disorders, Oncology, and Growth Hormone); By Manufacturer (Contract Research and Manufacturing, In-house Manufacturing); and Region –Analysis of Market Size, Share & Trends for 2016 – 2019 and Forecasts to 2030
Product Overview
Biosimilar drugs are extremely identical to permitted on-going biologic drugs. “Copied” or approved copies of reference biological products under patented products are biosimilars or following-on-biologics. A critical part of the overall production process is the production and evaluation of bio-referential biologics. In the conservation of feasibility and consistency between initial and biosimilar goods the rules for biosimilars play an important role.
Market Highlights
U.S Biosimilars Market is estimated to reach USD XXXX Million by 2030 from USD XXXX Million in 2019. The market is anticipated to grow at a CAGR of XX% during the forecast period, i.e., 2020-2030. A growing number of patients affected by such illnesses would result in an increased incidence of chronic diseases throughout the world, in particular in developed countries, due to the increased sedentary lifestyle and the increasing practice of fast-food consumption.

Global Next-Generation Antibody Therapeutics Market: Market Segments: By Therapeutic Area (Oncology Autoimmune/Inflammatory); By Technology (Antibody-Drug Conjugates (ADCs), Bispecific Antibodies, Fc-engineered Antibodies, Antibody Fragments and Antibody-like Proteins & Biosimilar Antibody Products);and Region – Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030
U.S Biosimilars Market: Segments
U.S market has been segmented on the basis of Product type, application, and by location. It has been further segmented by countries into Northern, Eastern, western and southern region.

Recombinant non-glycosylated proteins segment is anticipated to register XX% of the volume share.
On the basis of product type the biosimilars market is segmented into: Recombinant non-glycosylated proteins and Recombinant glycosylated proteins. Recombinant non-glycosylated proteins are further segmented into human growth hormone, granulocyte colony-stimulating factor, insulin and interferon. The Recombinant non-glycosylated proteins market held a market share of XX% in the year 2019 and is expected to grow at fastest pace during the forecast period due to technological developments in cell technology and high-throughput logical methods are likely to facilitate efficient manufacturing of recombinant non-glycosylated proteins leading to improved sales.

Biosimilars Market in India 2017
U.S Biosimilars Market: Market Dynamics
Cost-Effectiveness to increase the demand for the market
With the lifestyle becoming a more sedentary and the growing number of people affected by chronic diseases, there needs to be an emphasis on reducing healthcare costs. Biosimilars are likely to play a crucial role as they are cost-effective and will save a huge amount of money becoming easily affordable for the general public.
Huge costs involved are expected to hinder the market demand
In the less-developed and emerging nations, enormous costs associated with the production of bio-similar drugs would likely hinder progress. In the lack of strict legislation, consumer commitment to a brand, doctors’ inability to prescribe biosimilars and others, the growth of the biosimilars market is further hindered by the lack of customers’ loyalty.

Healthcare Analytical Testing Services Market Outlook 2030: Industry Insights & Opportunity Evaluation, 2019-2030
U.S Biosimilars Market: Region

U.S to hold the largest market share during the forecast period
U.S accounted for major share of XX% during 2019 and is estimated to dominate the biosimilars market. The American market is to be propelled due to the prevalence of key research & development centers. Moreover, US being the most developed and economically stable nation and major players belonging to the state are supposed to boost the overall growth in the development of biosimilars. Asia-Pacific is anticipated to register a healthy growth rate during the forecast period due to increasing geriatric population, ill-eating habits of the millennial, rising consumption of tobacco and alcohol. These factors are to fuel the overall market growth.
The region segment can be further divided into four major types including Eastern US, Northern US, Western US and Southern US.
U.S Biosimilars Market: Competitive landscape
Biosimilar key players leverage advantages in orphan biosimilars. As inexpensive care choices for patients in need of biologics, biosimilars are growing rapidly. As new treatments are highly prevalent, corporations have a heightened aim to direct progress in biosimilars.
U.S Biosimilars Market: Impact of COVID-19
There are many experimental regimens world-wide to try to find suitable for Covid-19. Hydroxychloroquine is used in one category of therapies, while antiviral drugs used in treating HIV are included in a second method for cure. The market for specialized antivirals and antimalarials has increased demand for both of these methods. The pharmaceutical companies must also be viewed as an indicator of the off-label for these drug groups.
Key Players
• Pfizer
o Company Overview
o Business Strategy
o Key Product Offerings
o Financial Performance
o Key Performance Indicators
o Risk Analysis
o Recent Development
o Regional Presence
o SWOT Analysis

• Apotex/Apobiologix
• Coherus Biosciences
• Merck & Co.
• Biogen
• Amgen
• Teva Pharmaceutical Industries
• STADA Arzneimittel
• Other prominent players
U.S Biosimilars Market Report also contains an analysis on:
U.S Biosimilars Market by segment:
• By Product Type
o Recombinant Non-Glycosylated Proteins
o Human Growth Hormone
o Granulocyte Colony-Stimulating Factor
o Insulin
o Interferon
o Recombinant Glycosylated Proteins
o Erythropoietin
o Monoclonal Antibodies
o Follitropin
o Low Molecular Weight Heparin
• By Application
o Haematology
o Oncology
o Autoimmune Disease
o Growth Hormone Deficiency
o Diabetes

• By Manufacturer
o In-house Manufacturing
o Contract Manufacturing
 US Biosimilars Market Dynamics
 US Biosimilars Market Size
 Supply & Demand
 Current Trends/Issues/Challenges
 Competition & Companies Involved in the Market
 Value Chain of the Market
 Market Drivers and Restraints

Additional information


Geography Covered

Date Published




Table of Contents

1. Executive Summary
2. US Biosimilars
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Market Dynamics
5.1. Growth Drivers
5.2. Restraints
5.3. Opportunity
5.4. Trends
6. Correlation & Regression Analysis
6.1. Correlation Matrix
6.2. Regression Matrix
7. Recent Development, Policies & Regulatory Landscape
8. Risk Analysis
8.1. Demand Risk Analysis
8.2. Supply Risk Analysis
9. US Biosimilars Industry Analysis
9.1. Porters Five Forces
9.1.1. Threat of New Entrants
9.1.2. Bargaining Power of Suppliers
9.1.3. Threat of Substitutes
9.1.4. Rivalry
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10. US Biosimilars Market
10.1. Market Size & forecast, 2019A-2030F
10.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.2. By Volume (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11. US Biosimilars Market: Market Segmentation
11.1. By Regions
11.1.1. US:
• By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.2. By Product type: Market Share (2020-2030F)
11.2.1. Recombinant Non-Glycosylated Proteins, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.2.2. Recombinant Glycosylated Proteins, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

11.3. By Application: Market Share (2020-2030F)
11.3.1. Chronic & Autoimmune Disorders, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.3.2. Blood Disorders, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.3.3. Oncology, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.3.4. Growth Hormone, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12. Company Profile
12.1. Pfizer
12.1.1. Company Overview
12.1.2. Company Total Revenue (Financials)
12.1.3. Market Potential
12.1.4. Global Presence
12.1.5. Key Performance Indicators
12.1.6. SWOT Analysis
12.1.7. Product Launch
12.2. Apotex/Apobiologix
12.3. Coherus Biosciences
12.4. Merck & Co.
12.5. Biogen
12.6. Amgen
12.7. Teva Pharmaceutical Industries
12.8. STADA Arzneimittel
12.9. Other prominent players
13. Consultant Recommendation
**The above given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.